Rapezzi Claudio, Gallo Pamela
Dipartimento Cardio Toraco Vascolare, Università degli Studi, Policlinico S. Orsola-Malpighi, Bologna.
G Ital Cardiol (Rome). 2009 Dec;10(11-12 Suppl 3):25S-27S.
Many large-scale studies demonstrated in aggregate that high-sensitivity C-reactive protein (hsCRP) levels are a strong, independent predictor of future vascular events and that hsCRP adds prognostic information on risk at all levels of LDL cholesterol, at all levels of the Framingham risk score, and at all levels of the metabolic syndrome. Moreover, hsCRP predicts risk of recurrent coronary events and has important prognostic value in acute coronary ischemia and after coronary interventions. The JUPITER study was aimed to determine whether long-term treatment with rosuvastatin (20 mg/die) will reduce the rate of major adverse cardiovascular events, defined as the combined endpoint of cardiovascular death, stroke, myocardial infarction, hospitalization for unstable angina, or arterial revascularization among individuals with LDL cholesterol levels < 130 mg/dl (3.36 mmol/I) who are at high risk because of an enhanced inflammatory response as indicated by hsCRP levels > 2 mg/I.
许多大规模研究总体表明，高敏C反应蛋白（hsCRP）水平是未来血管事件的一个强有力的独立预测指标，并且hsCRP在所有低密度脂蛋白胆固醇水平、所有弗雷明汉风险评分水平以及所有代谢综合征水平上都能增加风险的预后信息。此外，hsCRP可预测复发性冠状动脉事件的风险，并且在急性冠状动脉缺血以及冠状动脉介入治疗后具有重要的预后价值。JUPITER研究旨在确定，对于低密度脂蛋白胆固醇水平<130mg/dl（3.36mmol/L）且因hsCRP水平>2mg/L表明炎症反应增强而处于高风险的个体，长期服用瑞舒伐他汀（20mg/日）是否会降低主要不良心血管事件的发生率，主要不良心血管事件定义为心血管死亡、中风、心肌梗死、因不稳定型心绞痛住院或动脉血运重建的综合终点。
